Business Operation · 2025
In this section22 topics
- Corporate Information4 items
- Dividend Policy2 items
- Major Shareholders1 item
- Business Strategies Overview5 items
- Material Changes & Developments1 item
- Use of Proceeds from Securities Offerings2 items
- Commitments Made in the Registration Statement1 item
- Group Operating-Structure Policy1 item
- Companies Where the Company Holds ≥10%1 item
- Shareholders with Potential Conflict of Interest1 item
- Relationships Among Major Shareholders2 items
- Shareholders' Agreement2 items
- Shareholding Diagram (Group Structure)3 items
- Income Structure3 items
- Product / Service Characteristics2 items
- Research & Development5 items
- Assets Used in the Business6 items
- Marketing Policy & Competition3 items
- Procurement of Products & Services2 items
- Projects Under Construction1 item
- Debentures & Bills of Exchange1 item
- Convertible Securities1 item
Corporate Information
Company Name
Bangkok Genomics Innovation Public Company Limited
Telephone
0-2261-2638
Website
https://www.bangkokgenomics.com/
BKGI_IR@bangkokgenomics.com
Dividend Policy
Dividend Policy
The Company has a policy of paying dividends to its shareholders at a rate of not less than 40.00% of the net profit based on the Company’s separate financial statements for each fiscal year, after deduction of corporate income tax and allocation to the statutory reserve as required by law.
However, the Company may consider paying dividends at a rate different from the stated policy depending on various factors, including the Company’s operating results, financial position, liquidity, working capital requirements for business operations, future business expansion plans, as well as overall economic conditions.
Historical Dividend Payments
| This Year | Last Year | 2 Years Ago | 3 Years Ago | Metric | Description |
|---|---|---|---|---|---|
| 0.08 | 0.09 | 0.07 | Net profit per share (Baht : Share) | Net profit per share (baht : share) | |
| 0.05 | 0.05 | 0.05 | Dividend per share (Baht : Share) | Dividend per share (baht : share) | |
| 0 | 0 | 0 | 0 | Dividend stock ratio (Number of original shares: dividend shares) | Ratio of stock dividend payment (existing share : stock dividend) |
| 0 | 0 | 0 | Dividend share value per share (Baht : Share) | Value of stock dividend per share (baht : share) | |
| 0 | 0 | 0 | Total dividend payment value (Baht : Share) | Total dividend payment (baht : share) | |
| 66.15 | 59.79 | 74.67 | Dividend payout ratio to net profit (%) | Dividend payout ratio compared to net profit (%) |
Business Strategies Overview
Chairman's Message
Dear Shareholders and Stakeholders,
The year 2025 marked another period in which businesses faced continued volatility in the global economy and evolving business environments. Uncertainty in international trade, trade policies of key partner countries, and the increase in import tariffs remained key factors exerting pressure on global trade. Nevertheless, the healthcare and medical sector continues to play a vital role in improving people’s quality of life and is expected to maintain its growth trajectory, driven by increasing global demand for healthcare services. This trend is further supported by the growing emphasis on preventive healthcare as well as government initiatives promoting the development of the medical and health technology industries. At the same time, Thailand is experiencing a continuous decline in its birth rate, which represents a structural factor that may affect the demand for certain healthcare services in the long term. As a result, industry operators need to adapt their business strategies and broaden their service offerings to align with the changing demographic structure.
Bangkok Genomics Innovation Public Company Limited (BKGI) remains committed to continuously enhancing its capabilities in genetic and genomic testing services. Over the past year, the Company has invested in new technologies and further developed its analytical processes to improve efficiency and accuracy in response to the growing demand for healthcare services and to support the advancement of precision medicine in Thailand. The Company operates a standardized medical laboratory and provides comprehensive genetic testing services covering all stages of life—from prenatal screening to genetic analysis for adult and elderly healthcare. At the same time, the Company continues to strengthen its organizational capabilities by enhancing the expertise of its personnel and adopting internationally recognized technologies to reinforce its competitiveness. In addition, BKGI views the ongoing industry changes as an opportunity to refine its business strategy, particularly through supportive policies from the National Health Security Office (NHSO), which have increased access to Down syndrome screening for pregnant women. This has led to a significant increase in testing volumes, thereby improving equipment utilization and reducing the cost per test. The Company therefore aims to expand its genetic testing platforms to develop into a comprehensive genomics solutions provider for hospitals as well as public and private healthcare organizations. This strategy will help diversify the Company’s revenue structure, including income from the sale and installation of laboratory instruments and recurring revenue from the supply of diagnostic reagents over the long term.
Finally, on behalf of the Board of Directors, the management team, and all employees of the Company, I would like to express my sincere appreciation to our shareholders, customers, business partners, and all stakeholders for their continued support and trust. The Company remains committed to strengthening collaboration with organizations across the healthcare industry to develop solutions that effectively respond to market needs. At the same time, we uphold strong corporate governance principles with transparency and accountability, while pursuing sustainable business operations by minimizing environmental impacts from laboratory operations and promoting efficient resource utilization. Through our services, we also strive to support preventive healthcare and contribute to improving public health. BKGI will continue to move forward with determination to achieve sustainable growth, create value for society, and deliver long-term returns to our shareholders.
Vision
Using professional and scientific expertise, making quality of life accessible for all.
Objectives
SCOPEs
We are dedicated to becoming a leader in the healthcare business, driving improvements in quality of life through our core mission:
S – Support Medical Institutions, Research Institutions, Pharmaceutical Companies, and other public and private partners.
C – Cooperate with referral laboratory centers across the territory.
O – Obtain ISO certificates related to business scopes.
P – Provide quality data with outstandingly competitive pricing using our expertise and scalable platform.
E – Ecosystem health and sustainability focused.
s – Support the development and implementation of the National Public Health Data Analysis to help optimize health treatment and services for the public.
Goals
To become a leader in providing innovative solutions for personal and public health using advanced technologies and to create lasting impacts for a healthier future.
Business Strategies
• Differentiation – Competitive advantage through quality service, reduced waiting times, and reasonable pricing.
• Recommend – Encouraging repeat purchases, word-of-mouth referrals, and expansion of new products and services to both existing and new customers.
• People – A team of highly knowledgeable, skilled, and experienced professionals in our core business.
• Technology – Cost efficiency driven by proprietary BGI & Branding technology. Customer
• Satisfaction – Trusted by customers and medical professionals, with direct distribution ensuring quality and reliability. Business Partner – Strong and strategic partnerships.
Material Changes & Developments
Material Changes & Developments
| Year | Description |
|---|---|
| 2,017 | • Registered on September 11, 2017, as Bangkok Genomics Innovation Co., Ltd. to engage in laboratory operations and provide medical diagnostic services. • Began offering fetal chromosomal abnormality screening from maternal blood under the NIFTY brand of BGI Genomics Co., Ltd. ("BGI Genomics"), a company in the BGI Group, by collecting customer samples and sending them for analysis at BGI Group’s laboratories abroad. |
| 2,018 | • Registered as a medical equipment importer and began importing key medical devices and genetic sequencing readers from companies in the BGI Group. • Restructured shareholding, with BGI Tech Solutions (Hong Kong), a company in the BGI Group, acquiring a 49% share. • Received an investment promotion certificate from the BOI for scientific testing services. • Obtained a license for a healthcare facility that does not admit patients for overnight stays under the name "Bangkok Genomics Medical Technology Clinic." |
| 2,019 | • Received Technology Transfer to provide NIFTY services from the BGI Group. • Began offering genetic decoding services to government agencies such as NSTDA, Chulabhorn Royal Academy, etc. • Started providing full-scale NIFTY testing and analysis services. |
| 2,020 | • Set up a laboratory and provide services related to COVID-19 pathogen testing. • Received accreditation for laboratory standards ISO 15189 and ISO 15190. |
| 2,021 | • Joined as one of the referral service units with the National Health Security Office (NHSO). |
| 2,022 | • BGI Tech Solutions (HK) transferred shares to BGI Health (HK), and BGI Health (HK) purchased shares from existing shareholders, increasing its ownership to 51%. • The extraordinary shareholders’ meeting no. 2/2022 approved a capital increase of 340 million shares: - 180 million shares allocated to existing shareholders in proportion. - 160 million shares to be offered for sale to the public. • Opened the second medical technology clinic. • Began offering basic health check-up services. • Expanded service offerings to include cancer gene screening, PGT-A testing, and COLOTECT screening. |
| 2,023 | • Successfully passed proficiency testing for BRCA1/BRCA2 gene testing for hereditary cancers using NGS technology. • Signed an MOU with BGI Shenzhen Co., Ltd. and INNOBIC (Asia) Co., Ltd., the biotechnology division of PTT Public Company Limited, to jointly establish an international life sciences innovation center and promote a colorectal cancer prevention project in its early stages in Thailand using the “COLOTECT” testing kit under BGI technology in March 2023. • Certified for ISO/IEC 27001:2022 Information Security Management System (ISMS) in March 2023. • Collaborated on research and development with NSTDA on the "Microbial Study Process in the Gut using NGS Technology with the DNBSEQ-G50 Machine, covering library preparation, genetic code verification, and data analysis through Bioinformatics Software" to study human gut microbiota in April 2023. • Signed an MOU with the Faculty of Medicine Siriraj Hospital, Mahidol University, BGI Health (HK) Co., Ltd., and Hemogen Hongkong Alpha Technology Limited (HGI) to jointly develop, study, and find methods to prevent and treat thalassemia in Thailand. • Became a network healthcare provider under the NHSO’s Lab Anywhere project, and BRCA1/BRCA2 genetic testing for breast cancer patients at high risk and first-degree relatives with a family history of mutation detection in June 2023. |
| 2,024 | • Bangkok Genomics Innovation Public Company Limited was registered on the Stock Exchange of Thailand on March 20, 2024. • Signed a Memorandum of Understanding (MOU) with Bumrungrad Hospital and BGI Shenzhen to strengthen genomics medical services. • Signed a Memorandum of Understanding (MOU) with the Department of Medical Sciences and BGI Health (Hong Kong) to exchange academic knowledge in medical fields, including clinical whole exome sequencing, fetal chromosomal abnormalities screening (NIPT), and genetic screening for thalassemia in Thailand. • Established a 99.994% owned subsidiary named "Omics Sphere Co., Ltd." on November 1, 2024. • Established a 99.996% owned subsidiary named "Comprehensive Care Limited." on November 5, 2024. • Established a 25.000% owned joint venture named "Edge Medical (Thailand) Co., Ltd." on November 7, 2024. • Established a 50.998% owned subsidiary named "Biovision Tech Co., Ltd." on December 23, 2024. |
| 2,025 |
|
Use of Proceeds from Securities Offerings
Is There Money Raised from a Securities Offering Still to Report On?
Yes
Offerings
| Type of Securities | Amount Raised Given As | Amount Raised (Million Baht) | Uses of the Money | Used as Declared? | Related Link |
|---|---|---|---|---|---|
| Equity Instruments | 2873 | 245.57 | 2026-12 · Objective: Working capital for business operations · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 74.39 · Expected amount type: 2873 · Start expected amount range: 245.57 | Y | https://www.set.or.th/en/market/news-and-alert/newsdetails?id=100962800&symbol=BKGI |
Commitments Made in the Registration Statement
Are There Commitments or Conditions from an Offering or Listing?
No
Group Operating-Structure Policy
Description
The Company has established an investment policy for subsidiaries or associated companies. The Company will invest in companies that have the same business objectives as the Company's core businesses or similar businesses, or businesses that support the Company's businesses, which will enable the Company to increase its operating results or profits. Or invest in businesses that benefit the Company by supporting the Company's core businesses to be more comprehensive in order to increase the Company's competitiveness. In overseeing subsidiaries or associated companies, the Company will send directors or executives with appropriate qualifications and experience in business operations to be directors or executives in subsidiaries and/or associated companies at least in proportion to the shareholding in each company to represent the management of such subsidiaries and associated companies. To set important policies and control the business operations of subsidiaries and/or associated companies, including establishing a supervisory mechanism through the disclosure of financial information, acquisitions and disposals, and intercompany transactions with such subsidiaries by using the relevant criteria for information disclosure and transactions in accordance with the rules and regulations of the relevant authorities. In this regard, the directors who are representatives of the Company must perform their duties in overseeing subsidiaries and/or associated companies to manage or operate in accordance with the policies set by the Company. In addition, monitoring to assess and examine prudently through adequate and appropriate internal control systems, including the use of discretion in accordance with the resolutions of the Board of Directors and/or the Shareholders' Meeting of the Company that approves important matters of subsidiaries and/or associated companies in order to maximize the benefits to the Company and for the sustainable growth of the Company.
Companies Where the Company Holds ≥10%
Companies (≥10% Holding)
| Company Name | Address | Province | Zip Code | Telephone | Business Type | Security Type | Shares | Paid-up Shares |
|---|---|---|---|---|---|---|---|---|
| Omicsphere Company Limited | 3689 Rama 4 Road, Phra Khanong, Khlong Toei District | Bangkok | 10110 | - | Trading, distributing, selling, exporting tools, equipment, raw materials, ingredients, components, and chemicals for laboratory use, such as Titrators and Magnetic Stirrers. | Common shares | 299,982 | 299,982 |
| Comprehensive Care Limited | 3689 Rama 4 Road, Phra Khanong, Khlong Toei District | Bangkok | 10110 | - | Advanced Therapy Medicinal Products related to Cell | Common shares | 49,998 | 49,998 |
| Biovision Tech Company Limited | 3689 Rama 4 Road, Phra Khanong, Khlong Toei District | Bangkok | 10110 | - | Providing consulting services in management and administration for all types of businesses, including individuals, groups of individuals, juristic persons, government agencies, and state enterprises. | Common shares | 20,399 | 20,399 |
| Edge Medical (Thailand) Company Limited | 3741 Rama IV Road, Phra Khanong, Khlong Toei District | Bangkok | 10110 | - | Engaging in the import and distribution of pharmaceuticals, chemicals, medical instruments, and all types of medical equipment (upon receiving permission from relevant authorities). | Common shares | 10,000 | 10,000 |
Income Structure
Product / Service Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue from operations | Total revenue from operations | 379,511.13 | 100 | 337,592.9 | 100 | 245,389.66 | 100 |
| Reproductive Health service | 232,966.54 | 61.39 | 233,135.7 | 69.06 | 207,107.38 | 84.4 | |
| Infectious Disease Service | 93 | 0.02 | 227.8 | 0.07 | 22,807.94 | 9.3 | |
| Other Screening Test Services | 22,317.15 | 5.88 | 17,942.09 | 5.31 | 1,868.94 | 0.76 | |
| Tech- Solution Services | 8,604.38 | 2.27 | 5,196.59 | 1.54 | 9,597.72 | 3.91 | |
| Advanced Therapy Medicinal Product Services | 3,663.55 | 0.97 | 0 | 0 | 0 | 0 | |
| Sale sequencers and reagent | 100,774.41 | 26.55 | 80,106.45 | 23.73 | 4,007.68 | 1.63 | |
| Sale of Advanced Therapy Medicinal Products | 9,158.88 | 2.41 | 0 | 0 | 0 | 0 | |
| Sale other | 1,933.22 | 0.51 | 984.27 | 0.29 | 0 | 0 | |
| Other | Others | 0 | 0 | 0 | 0 | 0 | 0 |
Export Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue | Total revenue | 379,511.13 | 100 | 337,592.9 | 100 | 245,389.66 | 100 |
| Domestic | Domestic | 376,875.64 | 99.31 | 336,308.72 | 99.62 | 243,513.22 | 99.24 |
| International | International | 2,635.49 | 0.69 | 1,284.18 | 0.38 | 1,876.44 | 0.76 |
Other Income
| Operating Other Income | Non-Operating Other Income | Share of Profit |
|---|---|---|
| 1710 · As of year: 7216.84 · Description: Total other income · As of yesteryear: 8272.95 · As of year before yesteryear: 1954.54 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 | 1712 · As of year: 7216.84 · Description: Other income not from operations · As of yesteryear: 8272.95 · As of year before yesteryear: 1954.54 | 1713 · As of year: -324.16 · Description: Share of profit · As of yesteryear: -84.75 · As of year before yesteryear: 0.0 |
Product / Service Characteristics
Business Type
3115
Business Groups
| Business Group | Description |
|---|---|
| Provision of services | 1.Reproductive Health Testing Services 1.1. Non-Invasive Prenatal Testing (NIPT) under the "NIFTY" Brand Non-Invasive Prenatal Testing (NIPT), also known as Non-Invasive Prenatal Screening (NIPS), is a screening test that detects chromosomal abnormalities in a fetus by analyzing fetal DNA fragments (cell-free fetal DNA) present in the mother’s bloodstream. This test assesses chromosomal abnormalities by comparing the ratio of chromosome pairs to normal population values. NIPT is suitable for pregnant women between 10 and 24 weeks of gestation. It requires only 8–10 ml of maternal blood, posing no risk of miscarriage, unlike amniocentesis. Results are available within 5–7 days. Our company offers NIPT under the "NIFTY" brand, authorized by the BGI Group. Using Next-Generation Sequencing (NGS) technology and advanced bioinformatics from BGI, this test provides highly accurate and reliable results. 1.2. Preimplantation Genetic Testing for Aneuploidies (PGT-A) Preimplantation Genetic Testing for Aneuploidies (PGT-A) is a genetic screening technique used during in vitro fertilization (IVF) to select embryos with normal chromosomal composition before implantation. This increases the chances of a successful pregnancy. The test employs Next-Generation Sequencing (NGS) to analyze all 23 chromosome pairs with high precision. It detects genetic abnormalities that may affect fetal development, including duplications and deletions that conventional methods might miss. NGS is a modern, highly effective option for individuals seeking to reduce the risks of failed pregnancies and genetic disorders that could impact the baby’s long-term health. 1.3. Carrier Screening for Genetic Disorders Our Carrier Screening test, offered under the "VISTA" brand (authorized by the BGI Group), utilizes Next-Generation Sequencing (NGS) to identify genetic mutations that could be passed to offspring. Many individuals are unaware they are carriers of hereditary diseases until their child exhibits symptoms. This screening detects mutations in over 1,200 genes associated with more than 1,200 genetic conditions, including sex chromosome-linked disorders. It follows the guidelines of The American College of Obstetricians and Gynecologists (ACOG) and can be performed before or during pregnancy. It is particularly recommended for couples planning to conceive. In the Thai population, this screening covers prevalent genetic conditions such as: - Thalassemia: A common inherited blood disorder in Thailand, affecting hemoglobin production and causing anemia. Approximately 30–40% of the population are carriers, with around 1% affected by the disease. Symptoms include pale skin, enlarged liver and spleen, and bone deformities. - Spinal Muscular Atrophy (SMA): A disorder caused by the degeneration of motor neurons, leading to muscle weakness and, in severe cases, respiratory failure. About 1.8% of the Thai population are carriers. - Congenital Hearing Loss: A genetic disorder affecting auditory function due to protein abnormalities in the inner ear. In Thailand, about 1.7 per 1,000 newborns are affected. 1.4. Thalassemia Genetic Screening (Thalassemia-Seq) Thalassemia is the most common inherited blood disorder in Thailand, with 30–40% of the population being carriers. It results from defective hemoglobin production, causing red blood cells to break down easily. Severe cases may require regular blood transfusions and iron-chelating medication. The VISTA Thalassemia-Seq test by BGI detects over 508 mutations in alpha- and beta-globin genes, along with more than 1,200 hemoglobin abnormalities. This screening is recommended for couples planning to conceive, helping prevent the inheritance of thalassemia in future generations. |
| 2.Infectious Related Testing Services | Our infectious disease testing services provide screening and diagnostic solutions to help control and reduce the spread of pathogens. We utilize internationally certified equipment and reagents that meet CE-IVD standards (which ensure quality and safety compliance under European Union regulations for in vitro diagnostic devices) and are approved by Thailand’s Food and Drug Administration (FDA). All tests are conducted in accredited laboratories, which meet proficiency testing standards for detecting genetic material of SARS-CoV-2 (COVID-19), Including screening for cervical cancer–causing pathogens using a self-collection kit (HPV DNA test - self collection kit) from the Department of Medical Sciences, Ministry of Public Health. The service details are as follows: 2.1 COVID-19 Detection via Real-Time PCR: This test detects SARS-CoV-2 using a nasopharyngeal (nose) and throat swab, analyzed in a laboratory. Results are available within 3 to 24 hours. 2.2 Cervical Cancer Screening with Self-Collection HPV DNA Test: This test detects Human Papillomavirus (HPV), the primary cause of cervical cancer in over 95% of cases. It screens for 14 high-risk HPV DNA strains with a sensitivity of 91.9% for detecting precancerous lesions. Patients can self-collect samples at home using a self-sampling kit and send them to our laboratory for expert analysis. Results are reported within five business days. |
| 3.Other Testing Services | 3.1 Cancer Screening Services Our company offers cancer screening services under the "SENTIS" brand, authorized by BGI Group. These services include Hereditary Cancer Screening, which detects genetic mutations that increase the risk of cancer. This test can be performed before any symptoms appear to assess genetic predisposition using Next-Generation Sequencing (NGS) technology. The screening covers 79 genes in men, associated with 22 types of cancer, and 74 genes in women, associated with 23 types of cancer. It includes commonly inherited cancers such as breast cancer, ovarian cancer, colorectal cancer, prostate cancer, and gastric cancer. In addition to hereditary cancer screening, the Cancer+ Discovery Panel identifies genes related to the response to more than 200 cancer drugs, helping optimize personalized treatment plans.
3.2 Whole Exome Sequencing (WES) Our company offers Whole Exome Sequencing (WES) under the "BGI-XOME" brand, authorized by BGI Group. This service detects genetic mutations linked to diseases using high coverage sequencing technology. The test helps researchers and physicians analyze specific genes efficiently, leading to faster clinical diagnosis. Since genetic disorders often respond better to early intervention, this test allows for timely diagnosis and treatment, improving patient outcomes. 3.3 Individual Genetic Testing Our company provides detailed personal genetic analysis using Microarray and Next-Generation Sequencing (NGS) technology under the "DNALL" brand. This test analyzes an individual's genetic profile, providing insights into ancestry, optimal exercise regimens, metabolism, nutritional requirements, disease risk predictions, personality traits, and skin health. The information obtained from this test can be used to customize lifestyle choices, improve diet and supplementation, optimize fitness plans, and tailor medical care based on genetic predispositions. 3.4 Cardiovascular Disease Risk Screening: TMAO Our company offers a cardiovascular disease (CVD) risk screening service by measuring Trimethylamine-N-oxide (TMAO) levels in the bloodstream using Mass Spectrometry. This screening follows CE-IVD standards to assess heart and vascular disease risks. Research has shown a strong correlation between TMAO levels and cardiovascular risk, making this test a faster and more effective way to evaluate risk compared to basic health check-ups. 3.5 Alzheimer's & Dementia Risk Screening Our company provides blood-based biomarker testing for Alzheimer’s disease and other dementias. This non-invasive method offers an alternative to PET scans and cerebrospinal fluid (CSF) analysis by detecting protein accumulation linked to neurodegenerative diseases. The test can identify Alzheimer’s risk up to 10 to 20 years before symptoms appear, allowing individuals to take preventive measures or seek early treatment. This test can also be used to monitor treatment effectiveness in patients undergoing therapy. 3.6 Immune System & Inflammation Testing Our immune system and inflammation testing evaluates chronic inflammation, immune deficiencies, and immune-related disorders by analyzing T cells, B cells, and NK cells, which play crucial roles in immune response. The test also measures cytokine levels, which are key inflammatory molecules. These insights help in diagnosing immune-related conditions and optimizing treatment plans. 3.7 Gut Microbiome Analysis & Probiotics Selection Our gut microbiome analysis examines microorganisms in the digestive system using stool samples. This test helps assess gut health, digestion, immunity, and metabolism. The results can be used to select personalized probiotics and dietary modifications to enhance overall well-being. 3.8 APOE Genotyping (Alzheimer’s Genetic Risk Test) Our company offers APOE genotyping, a genetic test that analyzes Apolipoprotein E (APOE) variants. This test helps assess the risk of Alzheimer’s disease and abnormal cholesterol metabolism. It can be performed at any age to aid in early prevention and disease management. Additionally, APOE genotyping plays a role in determining the suitability of Alzheimer's treatments. 3.9 Telomere Length Test Our telomere length test measures the length of telomeres, which are protective structures at the ends of chromosomes. Telomere shortening is associated with aging and chronic diseases. This test helps assess cellular health, providing insights into biological aging and potential health risks. 3.10 Biological Age Testing with Epigenetics - Methylation Panel Developed by True Diagnostics in the U.S., this test uses Epigenetic Clocks to determine Biological Age, which differs from Chronological Age. It analyzes DNA methylation, a key process influencing cellular aging. The panel includes assessments of biological age, aging rate, immune system health, telomere length, and personalized lifestyle recommendations for slowing aging. |
| 4.Tech Solution Services | All living organisms share the same fundamental process for transferring and utilizing genetic information, known as the Central Dogma. This process involves three key components: DNA, RNA, and protein. Initially, DNA is transcribed into a new strand called RNA, which is then translated into protein that the body can use. These steps occur in a specific sequence and are closely connected, forming a continuous process. Studying each step in detail leads to a deeper understanding of the biological mechanisms that occur within living organisms.
|
| Provision of advanced medical services. | The Company provides advanced medical solutions, with a focus on manufacturing systems for Advanced Therapy Medicinal Products (ATMPs) in compliance with Good Manufacturing Practice (GMP) standards. These systems utilize closed automated technologies to support the production of cell therapy and gene therapy products. Such solutions are designed to enhance efficiency and consistency in manufacturing processes, reduce the risk of contamination, and support quality control at every stage of production, which are critical factors for highly complex medical products. In addition, closed automated systems enhance scalability to meet both clinical and commercial demands, while supporting the operations of hospitals, research institutions, and participants in the life sciences industry. |
| Sale and distribution of equipment and products | Our company imports and distributes legally authorized medical devices and products related to our services. These include comprehensive genetic testing kits, Beta-thalassemia real-time PCR (qPCR) test kits, cell-free DNA (cfDNA) collection tubes, and Yumeta Probiotics Powder supplements. In the future, we plan to expand our product range to offer more genetic testing solutions. The details of our current products are as follows: 1. Comprehensive Genetic Testing Solutions We offer a full set of equipment and reagents for genetic screening, including a genetic sequencer, DNA extraction and preparation systems, genetic data processing and analysis software, DNA extraction reagents, sequencing preparation reagents, and genetic sequencing reagents. 2. Beta-thalassemia Real-Time PCR (qPCR)
3. Cell-Free DNA (cfDNA) Collection Tubes
4. Yumeta Probiotics Powder Supplements
The product is certified by Thailand's Food and Drug Administration (FDA). 5. Distribution of Solutions for Cell and Gene Therapy Manufacturing The Company distributes solutions for the manufacturing of cell and gene therapies, covering CAR T and other types of cell therapies. The distributed solutions are designed to support standardized and traceable manufacturing processes, as well as to facilitate systematic production management, ranging from sample preparation and cell culture or modification to quality control. In addition, the Company distributes end-to-end automated biobank solutions to support the efficient storage and management of biological samples. These solutions help reduce human error, enhance accuracy in sample storage and tracking, and support research, drug development, and precision medicine. In this regard, in the future (from 2027 onwards), the Company plans to provide automated biobanking services for biological sample storage and to distribute other ATMP products. |
Research & Development
Has R&D Policy (Y/N)
No
R&D Cost — Label
Research and development (R&D) expenses over the past 3 years (Million Baht)
R&D Cost — This Year
1.72
R&D Cost — Last Year
1.28
R&D Cost — 2 Years Ago
0.7
Assets Used in the Business
Permanent Assets — Description
The company’s property, plant, and equipment used in its business operations have a net book value, after depreciation, as shown in the financial statements as of December 31, 2025, amounting to 56.24 million Baht.
Permanent Assets — Appraisal
| Asset | Ownership | Obligation | Appraisal Value | Description |
|---|---|---|---|---|
| Building improvements | Owner of the property rights | No | 7.09 | - Building Improvements - Office Building (5th and 6th Floors): Net book value of 0.50 million Baht.
- Building Improvements - Single-Story Laboratory (Branch 2) : Net book value of 3.64 million Baht.
- Building Improvements - Four-Story Laboratory (Branch 1) : Net book value of 2.65 million Baht.
- Building Improvements - Warehouse : Net book value of 0.30 million Baht.
|
| Office equipment and furniture | Owner of the title | No | 5.11 | - Computer Equipment and Server Systems: 2.39 million Baht
- Telecommunications and Internet Hardware: 0.70 million Baht
- Air conditioning units: 0.36 million Baht
- Others: 1.66 million Baht |
| Laboratory equipment and furniture | Owner of the title | No | 41.17 | - Genetic material packaging machine: 1.17 million Baht
- Quality Control - QC: 4.21 million Baht
- Library Preparation System: 6.39 million Baht
- Genetic material amplification machine: 4.11 million Baht
- Genetic sequencing machine: 15.82 million Baht
- Advanced Immunoassay Analyzer: 2.26 million Baht
- Bioinformatics & Data Management: 1.20 million Baht
- Others: 6.01 million Baht |
| Vihecle | Owner of the title | No | 2.87 |
Intangible Assets — Description
As of December 31, 2025, the Company's intangible assets used in business operations amounted to 22.94 million Baht.
Intangible Assets — Appraisal
| Asset | Type | Type (if Other) | Appraisal Value |
|---|---|---|---|
| Software Computer | Software | 2.88 | |
| Patents and Project Development Costs. | Others | Patents and Project Development Costs. | 20.06 |
Has Subsidiaries Investment Policy (Y/N)
Yes
Subsidiaries Investment Policy — Description
Bangkok Genomics Innovation Public Company Limited (“the Company”) invests in both publicly listed and privately held companies. The Company's investments include equity, hybrid financial instruments, and debt securities.
1. Target Companies and Entities
1.1 Newly established companies and/or entities, both domestically and internationally.
1.2 Existing companies and/or entities, both domestically and internationally. Investment Methods The Company employs various investment approaches, including: Greenfield Projects (newly initiated investments) Joint Ventures Mergers & Acquisitions (M&A) Amalgamations Asset Purchases Asset Swaps
2. Investment Returns
The Company seeks investment returns in the form of profits, capital gains, dividends, and/or interest income.
3. Investment Criteria
3.1 Aligns with the Company's goals, vision, and strategic growth plan by investing in businesses with sustainable revenue generation and stable long-term growth.
3.2 Focuses on businesses with growth potential that aligns with the Company's core competencies. These businesses should be capable of self-funding in the medium and long term without relying on financial support from the Company.
3.3 Ensures a minimum Return on Investment (ROI) of 20% per year, averaged over five years. If the ROI falls below this threshold, an investment plan must be presented to the Board of Directors for review and approval.
3.4 Establishes clear investment boundaries and manages risks by diversifying into businesses with strong operational advantages while assessing regional and country-specific investment risks.
3.5 Focuses on medium to long-term investments that enhance and add value to the Company.
4. Risk Management and ControlRisk Management and Control
4.1 Regularly provide investment status reports to the Board of Directors for acknowledgment and approval.
4.2 Prepare periodic financial reports, including performance results, budgets, and forecasts at both the company and project levels.
4.3 Comply with relevant regulations, including:
(1) Adherence to applicable laws and regulations in each jurisdiction.
(2) Compliance with applicable accounting standards.
(3) Adherence to the Company's Delegation of Authority (DOA) guidelines.
Marketing Policy & Competition
Reporting Mode
3117
Marketing Policy (Overall)
Policy on Marketing Activity Organization to Stimulate Revenue
1) The company will allocate a budget and develop a plan for marketing activities aimed at stimulating revenue and enhancing the company’s image.
2) The establishment of promotions must be documented in a memorandum, specifying the details of the products and services, conditions for the promotion, the start and end dates, budget, and expected outcomes. Written approval must be obtained from the authorized personnel.
3) The sales department is responsible for overseeing all promotions. A control register must be created, detailing the name of the event, duration, and the criteria used for organizing the activity.
4) Once the sales department has organized the activity, a summary report detailing the event, budget spent, comparison with the original plan, and the outcome must be prepared. This report must be submitted to the authorized personnel for review and signed off, and a copy must be sent to the Chief Officer for the relevant department for acknowledgment after the completion of the activity.
5) In cases where a promotion is extended, a memorandum requesting written approval from the authorized personnel must be prepared.
Industry & Competition (Overall)
The laboratory industry in 2025 continues to face intense competition driven by rapid technological advancements, increasingly stringent regulatory requirements, and the growing demand for laboratory testing services. Domestic operators also face challenges related to limitations in investment capital, technological capabilities, and marketing strategies when compared with multinational and foreign companies that possess stronger financial resources and technological advantages.
In addition, medical equipment manufactured domestically has not yet been widely accepted among medical professionals. As a result, the industry continues to rely on imported advanced technologies for service delivery and production processes, which may lead to higher costs of products and services in line with the increasing complexity of such technologies. Key factors affecting competitive conditions in the industry include:
1. Advancements in Medical Technology and Digital Transformation
Advancements in laboratory technologies, such as Next Generation Sequencing (NGS), automation systems, and bioinformatics data analysis, require operators to continuously invest in modern equipment and technologies to enhance accuracy, efficiency, and turnaround time. In addition, the adoption of advanced technologies such as Artificial Intelligence (AI), advanced analytics, and Laboratory Information Management Systems (LIMS), as well as emerging digital health trends including Telemedicine and At-home Diagnostic Kits, play an important role in improving service quality and operational efficiency, thereby strengthening the competitiveness of industry operators.
2. Regulatory Requirements and Laboratory Standards
The medical laboratory industry is subject to regulatory oversight and must comply with relevant standards and requirements, particularly international standards such as ISO 15189 for medical laboratories and ISO 17025 for testing and calibration laboratories. These standards serve as key indicators of the quality, accuracy, and reliability of laboratory results. Laboratories that consistently maintain high standards of quality and effective quality control systems are better positioned to build trust and confidence among physicians and service users, which represents an important competitive advantage.
3. Technology Costs and Competition in Pricing and Service Quality
Advanced medical equipment and technologies are largely imported, resulting in operational costs that may fluctuate in line with technology prices, exchange rates, and equipment complexity. At the same time, the laboratory industry faces competition in terms of pricing, quality of test results, turnaround time, and service standards. Operators therefore need to manage costs efficiently while continuously improving service quality and differentiating their services to maintain competitiveness and strengthen trust among physicians and service users.
4. Mergers, Acquisitions, and Strategic Partnerships
Trends in mergers, acquisitions, and strategic collaborations among laboratories, hospitals, research institutions, and healthcare partners have continued to increase as operators seek to expand service capabilities, develop new diagnostic services, and create additional business opportunities. Larger operators generally benefit from economies of scale, modern infrastructure, and broader service networks, which support business growth and enhance their competitive position within the industry.
5. Development of Specialized Professionals
Laboratory services require personnel with specialized knowledge, expertise, and professional experience. Operators therefore place significant emphasis on the continuous development of employee skills and professional competencies to keep pace with technological advancements and evolving industry requirements. Such efforts are essential to maintaining service quality and sustaining long-term competitiveness.
Procurement of Products & Services
Reporting Mode
3117
Procurement (Overall)
The company procures tools, equipment, and related products used in its operations by importing them from companies within the BGI group, as well as from other manufacturers/suppliers both domestically and internationally. The selection process focuses on choosing suppliers that meet high standards, offer reliable products, and are certified for quality assurance.
Projects Under Construction
Has Projects Under Construction (Y/N)
No
Debentures & Bills of Exchange
Has Debentures (Y/N)
No
Convertible Securities
Has Convertible Securities (Y/N)
No
